57 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
25
Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators.
Gwangju Institute of Science and Technology (Gist)
3
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists.
University of Camerino
6
Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.
Gwangju Institute of Science and Technology
1
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
University of Bonn
52
Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.
Roche Palo Alto
32
Discovery of P2X3 selective antagonists for the treatment of chronic pain.
AstraZeneca
63
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.
University of Bonn
2
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Abbott Laboratories
5
Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist.
Institute of Science and Technology
2
Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques.
Louis Pasteur University
44
Purine and pyrimidine (P2) receptors as drug targets.
National Institute of Diabetes
36
Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
Roche Palo Alto
26
Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
Roche Palo Alto
38
Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy.
Gwangju Institute of Science and Technology
22
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
Northwest University
1
Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.
Roche Palo Alto
16
Unveiling the Structure-Activity Relationships at the Orthosteric Binding Site of P2X Ion Channels: The Route to Selectivity.
European Institute For Molecular Imaging (Eimi)
21
AI-based prediction of new binding site and virtual screening for the discovery of novel P2X3 receptor antagonists.
Gwangju Institute of Science and Technology
16
Structure-Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2
National Institute of Diabetes and Digestive and Kidney Diseases
38
Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.
Shionogi
40
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.
Shionogi
15
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
National Institute of Diabetes and Digestive and Kidney Diseases
66
Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.
University of Bonn
57
Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion.
Gwangju Institute of Science and Technology (Gist)
27
New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones.
Gedeon Richter
72
New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.
Gedeon Richter
26
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.
Shionogi
9
Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs.
Universit£T Bonn
4
A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.
National Institute of Diabetes and Digestive and Kidney Diseases
34
Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells.
Gwangju Institute of Science and Technology (Gist)
35
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening.
Shionogi
503
COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
Dong-A St Co.
18
S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7
Consejo Superior De Investigaciones Cientificas
11
Synthesis, biological evaluation and in silico studies of 5-(3-methoxybenzylidene)thiazolidine-2,4-dione analogues as PTP1B inhibitors.
Panjab University
26
4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
Novartis
1
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
Respivert
22
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.
Vanderbilt University
4
Ethylene biosynthesis: processing of a substrate analog supports a radical mechanism for the ethylene-forming enzyme.
Duke University